Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (Pluristem)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: Pluristem is a bio-therapeutics company in the development stage, focused on commercializing allogeneic cell therapy products derived from human placenta. The company utilizes a proprietary 3D bioreactor system (PluriX) to expand placental adherent stromal cells (ASCs). Its lead product candidate, PLX-PAD, is in Phase I clinical trials for the treatment of Critical Limb Ischemia (CLI), a severe form of Peripheral Artery Disease (PAD). The company has no commercial product sales and relies on equity financing and government grants.
Key Financial Metrics
| Metric (in thousands USD) | Fiscal Year 2010 | Fiscal Year 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,453) | $(6,636) |
| Loss Per Share (Basic & Diluted) | $(0.44) | $(0.63) |
| Research & Development Expenses (Net) | $4,301 | $3,141 |
| General & Administrative Expenses | $3,138 | $3,417 |
| Cash and Cash Equivalents (End of Period) | $1,583 | $2,339 |
| Short-Term Bank Deposits | $913 | $0 |
| Total Current Assets | $3,605 | $2,935 |
| Total Current Liabilities | $1,281 | $840 |
| Working Capital | $2,324 | $2,095 |
| Accumulated Deficit | $(40,105) | $(32,652) |
Cash Flow Summary (FY 2010):
- Operating Activities: Used $5,408 (primarily salaries and clinical trial costs).
- Investing Activities: Used $1,296 (equipment purchases and short-term deposits).
- Financing Activities: Generated $5,948 (proceeds from private placements in July 2009, October 2009, and April 2010).
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 12% to $7.45 million, driven primarily by a 37% increase in net R&D expenses to support Phase I clinical trials and preparation for Phase II.
- R&D Expansion: R&D personnel increased by 50% (14 new hires), and a new research lab was built. Gross R&D spending increased, partially offset by increased government grants from the Israeli Office of the Chief Scientist (OCS).
- General & Administrative (G&A) Decrease: G&A expenses decreased by 8% to $3.14 million, primarily due to a reduction in stock-based compensation expenses.
- Liquidity Position: Cash and cash equivalents decreased by $756,000 year-over-year, despite raising approximately $6.5 million in gross proceeds from equity financings during the year. The company maintained a working capital surplus of $2.32 million.
- Stock Issuance: The company issued significant shares in three private placements during the fiscal year, increasing the weighted average number of shares outstanding and diluting loss per share.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance:
- The company does not expect to generate product revenues in the next 12 months. Commercialization is estimated to be at least three years away.
- Management estimates operational cash expenses for the next 12 months to be approximately $7.0 million ($5.0 million for R&D and $2.0 million for G&A).
- The company believes existing capital resources, combined with approved R&D grants (including a $2.5 million OCS grant and a $150,000 EU grant), will sustain operations until at least the first quarter of calendar year 2011.
Going Concern Warning:
The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to the lack of revenue, history of losses, and dependence on external financing. If additional financing is not obtained, the company may be forced to cease operations.
Key Risks:
- Regulatory Approval: No assurance that PLX-PAD or other candidates will receive FDA or EMA approval. Clinical trials may fail to demonstrate safety or efficacy.
- Capital Requirements: Continued need to raise capital through equity offerings, which will result in dilution to existing shareholders.
- Intellectual Property: Reliance on patents that may expire (earliest in 2020) and potential infringement claims.
- Geopolitical Risk: Principal R&D facilities are in Israel, exposing the company to regional political and military instability.
- Legal Contingency: A potential conflict exists regarding a 2007 financing agreement that restricted share sales below a certain price floor. The company proceeded with sales below this floor, issuing warrants to investors to mitigate potential litigation, though the outcome remains uncertain.
Investor Verification Checklist
- Cash Runway: Verify if the company has raised additional capital since the filing date to extend operations beyond the projected Q1 2011 limit.
- Clinical Trial Status: Confirm the final results of the Phase I PLX-PAD trials and the timeline for initiating Phase II trials.
- Grant Funding: Verify the receipt and utilization of the $2.5 million OCS grant and the EU FP7 grant mentioned in the outlook.
- Legal Resolution: Check for any updates regarding the potential litigation risk associated with the 2007 financing agreement price floor provision.
- Dilution Impact: Monitor future equity offerings and the impact on existing shareholder ownership percentages.